Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rinatabart sesutecan versus investigator's choice platinum-based chemotherapy with or without bevacizumab in recurrent platinum-sensitive ovarian cancer
NL-OMON61616Phase 3Not yet recruiting
- Sponsor
- Genmab
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rinatabart sesutecan, bevacizumab, carboplatin and paclitaxel in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Genmab. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rinatabart sesutecanbevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON61616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61616.